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dA new automated method for the quantitative analysis of cyproterone acetate (CPA) in human plasma has been developed using on-line solid
hase extraction (SPE) prior to the LC–MS/MS determination. The method was based on the use of a pre-column packed with internal-surface
eversed-phase material (LiChrospher RP-4 ADS, 25 mm × 2 mm) for sample clean-up coupled to LC separation on an octadecyl silica
tationary phase by means of a column switching system. A 30l plasma sample volume was injected directly onto the pre-column using
mixture of water, acetonitrile and formic acid (90:10:0.1 (v/v/v)) adjusted to pH 4.0 with diluted ammonia as washing liquid. The analyte
as then eluted in the back-flush mode with the LC mobile phase consisting of water, methanol and formic acid (10:90:0.1 (v/v/v)). The
ispensing flow rates of the washing liquid and the LC mobile phase were 300l min−1. Medroxyprogesterone acetate (MPA) was used as
nternal standard. The MS ionization of the analytes was achieved using electrospray (ESI) in the positive ion mode. The pseudomolecular
onic species of CPA and MPA (417.4 and 387.5) were selected to generate daughter ions at 357.4 and 327.5, respectively. Finally, the
eveloped method was validated according to a new approach using accuracy profiles as a decision tool. Very good results with respect to
ccuracy, detectability, repeatability, intermediate precision and selectivity were obtained. The LOQ of cyproterone acetate was 300 pg ml−1.
2004 Elsevier B.V. All rights reserved.
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. Introduction
The on-line coupling of mass spectrometry to liquid chro-
atography (LC–MS) is a powerful technique used for drug
etermination in various biological fluids [1–3]. Its high sen-
itivity and selectivity are well-known advantages. Some
f them also involve the on-line coupling of solid phase
xtraction to liquid chromatography for sample clean-up
4–5].
The column-switching technique is an interesting alterna-
ive to off-line approaches for the preparation of biological
amples. The role of precolumn is to retain selectively the
∗ Corresponding author. Tel.: +32 4 3664346; fax: +32 4 3664347.
E-mail address: jcrommen@ulg.ac.be (J. Crommen).
analytes. After rotation of the switching valve, the analytes
are transferred to the analytical column to be individually
quantified [6].
A new concept in LC packing materials for bioanalyt-
ical purposes was introduced in 1985 by Pinkerton and
coworkers [7,8]. Boos et al. introduced a new class of
restricted access material [9–12] called alkyl-diol silica
(ADS) that can be packed in small precolumns used for
the clean-up of protein-rich samples in column switching
systems.
Such restricted access supports, packed in small pre-
columns, have been successively applied to the individual de-
termination of drugs enantiomers in plasma samples [13,14].
The drug molecule studied in this paper is cypro-
terone acetate (6-chloro-1,2-dihydro-17-hydroxy-3′H-
021-9673/$ – see front matter © 2004 Elsevier B.V. All rights reserved.
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cyclopropa[1,2]-pregna-1,4,6-triene-3,20-dione acetate)
[24]. In practice, the usual dosage is 100 mg, twice daily
for the treatment of prostate carcinoma [15], or 2 mg for the
treatment of woman acne and hirsutism [16]. The average
concentration of CPA detected in plasma after the adminis-
tration of a dosage of 2 mg of CPA per day (Diane-35®) in
combination with 35g of an estrogenic compound leads to
a maximum plasma level (Cmax) of 15 ng ml−1 at 1.6 h [17].
Several LC methods have been developed for the quan-
titative analysis of CPA in pharmaceutical forms [18,19] or
in biological fluids using liquid–liquid extraction [20–22] or
solid-phase extraction in a column switching system [23,24]
for sample clean-up. For all these bioanalytical methods
based on UV detection, the limit of quantification was higher
than 1 ng ml−1. The introduction of MS detection should lead
to a significant improvement in detectability and selectivity
as well as to a reduction of the analysis time.
A novel approach based on the accuracy profile as de-
cision tool has been used for the validation of the present
method [25,26]. By this approach, using two-sided 95%
-expectation tolerance intervals for the total measure-
ment error, the performance of the procedure can be better
visualized.
The aim of this work is to develop and validate a fully au-























Fig. 1. (A) Structure of cyproterone acetate. Molecular weight:
416.95; molecular formula: 6-chloro-17-hydroxy-1,2-methylenepregna-
4,6-diene-3,20-dione acetate; (B) structure of medroxyprogesterone ac-
etate; molecular weight: 386.53; molecular formula: (6)-17-hydroxy-6-
methylpregn-4-ene-3,20-dione acetate.
An integrated column switching system coupled to a
capillary liquid chromatographic apparatus (HP Series 1100,
Agilent Technologies) consisting in a degasser, a micro
quaternary pump, a micro ALS model as injector and finally
an additional integrated six-port micro switching valve
(Colcom model) was used. The washing liquid used for the
sample pre-treatment was delivered by a model pump 302
from Gilson (Rijswijk, The Netherlands).
The MS/MS ionization of the analytes was achieved by
electrospray (ESI) in the MRM positive ion mode using a
triple quadrupole mass detector (Quatro Ultima) purchased
from Micromass (Wijtenshaw, UK). The main MS parame-
ters were as follows: source temperature: 150 ◦C, capillary
and cone voltages: 3.20 and 50 V, respectively, desolvation
temperature: 400 ◦C, cone gas flow: 170 L h−1, and finally
the desolvation gas flow: 410 L h−1. The resolution of the
different quadrupoles was also optimized (<0.5 amu). The
pseudomolecular ionic species of CPA and MPA (417.4 and
387.5) were selected to generate daughter ions at 357.4 and
327.5, respectively.
The plasma sample was first centrifuged at 4500 rpm for
10 min and 900l of the supernatant were used for sample
spiking. All the other operations were then executed auto-
matically.
The sample preparation was performed in two steps:
(yproterone acetate in human plasma using MS/MS detection
n order to improve the sensibility obtained in our previous
ork [24].
. Experimental
.1. Chemical, reagents and apparatus
Cyproterone acetate (CPA) and medroxyprogesterone ac-
tate (MPA) were purchased from Sicor (Lerma, Mexico) and
erta (Braine-L’Alleud, Belgium), respectively. Acetonitrile,
ethanol, ammonium acetate, diluted ammonia and formic
cid were purchased from Merck KGaA (Darmstadt, Ger-
any). The water was purified on a Milli-Q system (Milli-
ore, Bedford, MA, USA) (Fig. 1).
The analytical column (100 mm × 2 mm i.d.) was packed
ith OmniSpher C18 (3m) stationary phase in a ChromSep
ystem from Varian (Sint-Katelijne-Waver, Belgium). The
obile phase was a mixture of water, methanol and formic
cid (10:90:0.1 (v/v/v)) delivered at 0.3 ml min−1.
The LiChroCart precolumn (25 mm × 2 mm i.d.) packed
ith LiChrospher RP-4 ADS (25m), was purchased from
erck KGaA (Darmstadt, Germany). The washing liquid was
mixture of water, acetonitrile and formic acid (90:10:0.1
v/v/v)) adjusted to pH 4.0 and dispensed at 0.3 ml min−1.
Both precolumn and analytical column were thermostated
t 25 ◦C in the temperature controlled oven. The sample rack
as cooled at 15 ◦C.
The prevalidation and validation data were analysed with
.noval, software version 1.0. (Arlenda, Belgium).1) Injection and washing of sample: Thirty microliters of
aliquot of plasma were injected. The sample was washed
for 14 min with a mixture of water, acetonitrile and
formic acid (90:10:0.1 (v/v/v)) adjusted to pH 4.0 with
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diluted ammonia. The flow rate was 0.3 ml min−1.
Macromolecules and hydrophilic endogenous com-
pounds were not retained and eliminated to the waste.
The analytes were retained on the precolumn. Mean-
while, the analytical column was equilibrated with the
analytical LC mobile phase.
(2) Elution of the analytes from the precolumn and LC anal-
ysis: After these 14 min, the valve was switched in order
to connect the precolumn to the analytical column. The
analytes were eluted in the back-flush mode by the LC
mobile phase. Four minutes later, the switching valve was
returned to its initial position and the precolumn was re-
equilibrated with the washing liquid. In the mean time,
the LC–MS/MS analysis was performed on the analytical
column.
2.2. Solutions
2.2.1. Stock solution of internal standard and
cyproterone acetate
A stock solution containing 1 mg ml−1 of medroxyproges-
terone acetate was prepared in acetonitrile. This solution was
diluted in a mixture of 90% of water and 10% of acetonitrile
in order to obtain an intermediate solution of 50 ng ml−1. The

























der to cover the whole range. Three repetitions were made at
each concentration level for 3 days.
3. Results and discussion
Owing to the use of a narrow bore column and the on-line
coupling to MS/MS, several parameters of the previously
published method had to be adapted [24] that led to a re-
evaluation of both LC conditions and sample pre-treatment.
3.1. Optimization of the LC conditions
The optimization of the LC conditions was carried out
by evaluating three different stationary phases: a Purospher®
STAR RP-18 e (125 mm × 2.0 mm i.d., 5m) from Merck
KGaA; a Nucleosil® 100-5 C18 AB (125 mm × 2.0 mm
i.d., 3m) from Macherey-Nagel and an OmniSpher® C18
(100 mm × 2.0 mm i.d., 3m) from Varian. The latter gave
the best results in terms of peak efficiency and symmetry and
was selected.
Optimized results with respect to sensitivity (gain by a
factor two) were obtained with methanol. The addition of



























w.2.2. Solutions used for method pre-validation and
alidation
One ml of the stock solution of cyproterone acetate was
hen diluted with a mixture of water and acetonitrile (90:10
v/v)) in a 100 ml flask in order to obtain a daughter solution
10g ml−1). This solution was then diluted with acetonitrile
n order to obtain intermediate concentrations used for plasma
piking.
For both pre-validation and validation, 50l of each solu-
ion were spiked to 900l of human plasma samples over the
onsidered range (from 0.3 to 50 ng ml−1). Fifty microliters
f the internal standard were then added to the samples, in
rder to have a final concentration of 2.5 ng ml−1.
For pre-validation, seven concentration levels were
elected, one at the estimated limit of quantification
0.5 ng ml−1), one below the selected LOQ (0.3 ng ml−1), one
t the maximal concentration studied (50 ng ml−1) and four
ntermediate concentrations (1, 5, 10 and 25 ng ml−1). In the
alibration range three repetitions were made at each concen-
ration level and three series of calibration were performed
n the pre-validation.
For validation, five concentration levels were selected for
he calibration curves, one at the estimated limit of quantifica-
ion (0.3 ng ml−1), one at the maximal concentration studied
50 ng ml−1) and four intermediate concentrations (0.5, 1, 10
nd 25 ng ml−1). The sequence of injections consisted in two
epetitions of each concentration level for 3 days.
Six concentration levels (0.3, 0.5, 1, 10, 25 and
0 ng ml−1) were selected for the validation standards in or-A mobile phase consisting of a mixture of 75% of
ethanol and 25% of water allowed to separate cyproterone
cetate and medroxyprogesterone acetate. The addition of
.1% formic acid increased the detector response of the ana-
ytes comparing with mobile phases adjusted to pH 4.0 and
.0.
However, after 200 automated injections, a relatively im-
ortant carry-over effect (±1%) was observed at the retention
imes of CPA and MPA. The interference could be reduced
y selecting a LC mobile phase made of water, methanol,
nd formic acid (10:90:0.1 (v/v/v)). A decrease of the flow-
ate and an increase of the column temperature did not give
ise to any significant improvement. Therefore, these param-
ters were kept at their initial values. Under these conditions,
he carry-over was reduced to less than 0.3% (for both sub-
tances), even after injections of standard solutions contain-
ng 50 ng ml−1 of CPA and 2.5 ng ml−1 of MPA. The high
roportion of methanol of the mobile phase led to the co-
lution of the analyte and the internal standard from the an-
lytical column. The principal risk of this co-elution is a po-
ential loss of ionization efficiency at low concentrations of
he analyte due to the presence of high concentrations of
he internal standard. However, no significant loss of ioniza-
ion efficiency was observed with CPA in the presence of
PA.
.2. Development of the sample preparation procedure
In order to develop a method for the determination of
PA in human plasma using a column-switching system
ith a precolumn packed with restricted access material, it
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was necessary to determine the most appropriate switching
times and to optimize the composition of the washing liquid
[24].
3.2.1. Elution proﬁle of CPA and selection of the
washing liquid
The response intensity for CPA was higher with a washing
liquid consisting of 90% of water, 10% of acetonitrile and
0.1% of formic acid than without formic acid. However, the
results were improved with the use of a liquid adjusted to pH
4.0 instead of 7.0. Under these conditions, the retention time
of CPA was higher than 120 min.
3.2.2. Elution proﬁle of blank plasma
The determination of the elution profile of blank plasma
was performed using a UV detector set at 220 and 280 nm,
respectively, and by injecting 30l of blank plasma samples.
The flow-rate was kept at 0.3 ml min−1.
A complete elution of proteins was achieved within 5 min
with a washing liquid made of water, acetonitrile and formic
acid (90:10:0.1 (v/v/v)) adjusted to pH 4.0 with diluted am-
monia. The valve switching time had to be increased to 14 min














The absolute analyte recovery was determined by compar-
ing peak areas obtained from freshly prepared plasma sam-
ples and those found by direct injection of standard solutions.
The absolute recovery for CPA was estimated at 99.4± 1.4%
(n = 9) in the whole concentration range.
3.3. Method validation
3.3.1. Stability
Samples exhibited good stability after a 1 month storage
at −18 ◦C and 48 h in the auto-sampler kept at 15 ◦C. The
accuracy calculated at three concentration levels (0.3, 1.0 and
50.0 ng ml−1) were estimated at 94.6 ± 1.6% (n = 9), 96.9 ±
1.3% (n = 9) and 100.4 ± 1.1% (n = 9), respectively.
3.3.2. Selectivity
The selectivity was evaluated by testing six different
sources of human plasma. Fig. 2 illustrates the selectivity by
comparing a blank plasma sample, one spiked with both CPA
and MPA and finally a plasma sample from a dosed patient at
T24 h spiked with the internal standard. Under the optimized
experimental conditions, the mean retention factors for CPA
and MPA were both equal to 3.0, as the two compounds co-






The two target substances were rapidly eluted from the
P-4 ADS precolumn due to the much stronger eluting
trength of the LC mobile phase (water–methanol–formic
cid, 10:90:0.1 (v/v/v)). It takes about 4 min to quantitatively
ransfer CPA and MPA from the precolumn to the analytical
olumn.
ig. 2. Method selectivity for the determination of cyproterone acetate in hum
nd 2.5 ng ml−1 of MPA; and (C) plasma from dosed patient at T24 h spiked
.d.), washing liquid: water–acetonitrile–formic acid (90:10:0.1 (v/v/v)) adju
ransfer step: 4 min. Column: OmniSpher C18 (100 mm × 2.0 mm i.d.) (3
.3 ml min−1, injection volume: 30l of plasma sample, temperature: 25 ◦C
cetate; CPA: cyproterone acetate.sma. Samples: (A) blank plasma; (B) spiked plasma with 25 ng ml−1 of CPA
5 ng ml−1 of MPA. Precolumn: LiChrospher RP-4 ADS (25 mm × 2.0 mm
H 4.0 with diluted ammonia, flow-rate: 0.3 ml min−1, loading step: 14 min,
obile phase: water–methanol–formic acid (10:90:0.1 (v/v/v)), flow-rate:
mode parameters: as described in Section 2.1. MPA: medroxyprogesterone
eing <0.3% for both substances after analysis of a plasma
ample spiked with 50 ng ml−1 of CPA and 2.5 ng ml−1 of
PA.
.3.3. Response function [25–27]
The validation results of the response function are pre-
ented in Table 1. A weighted linear regression (1/X2) with
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Table 1
Validation results
Day 1 Day 2 Day 3
Response function
Slope 3.72 × 10−4 3.72 × 10−4 3.71 × 10−4
(k = 3, m = 6, n = 3) Intercept 5.80 × 10−2 5.83 × 10−2 5.75 × 10−2
0.3–50 ng ml−1 r2 0.9996 0.9996 0.9996
Trueness (k = 3; n = 3) Absolute bias, pg ml−1 (relative bias (%))
0.3 ng ml−1 3.51 (1.2)
0.5 ng ml−1 −0.72 (−0.1)
1.0 ng ml−1 16.2 (1.6)
10 ng ml−1 −599.7 (−6.0)
25 ng ml−1 620.3 (2.5)
50 ng ml−1 2069 (4.1)
Precision (k = 3; n = 3) Repeatability, R.S.D. (%) Intermediate precision, R.S.D. (%)
0.3 ng ml−1 1.5 1.5
0.5 ng ml−1 0.9 1.2
1.0 ng ml−1 1.2 1.6
10 ng ml−1 0.5 0.5
25 ng ml−1 0.4 0.4
50 ng ml−1 0.4 0.4
Accuracy (k = 3; n = 3) -Expectation tolerance limit, ng ml−1 (%)
0.3 ng ml−1 0.293–0.314 (−2.4 to 4.7)
0.5 ng ml−1 0.483–0.516 (−3.4 to 3.1)
1.0 ng ml−1 0.968–1.065 (−3.2 to 6.5)
10 ng ml−1 9.275–9.525 (−7.2 to −4.7)
25 ng ml−1 25.39–25.85 (1.6–3.3)
50 ng ml−1 51.57–52.57 (3.1–5.1)
LOQ (ng ml−1) 0.3
LOD (ng ml−1) 0.12
six concentration levels was used and its goodness of fit is
illustrated in Fig. 3.
3.3.4. Trueness
As can be seen from the results in Table 1 trueness was
expressed in terms of absolute bias (pg ml−1) or relative bias
(%) and was assessed by means of validation standards in the
matrix at six concentration levels (m = 6) ranging from 0.3 to
50.0 ng ml−1 (k = 3, n = 3). Compared to the regulatory re-
quirements fixed [27], the proposed method was true enough
Fig. 3. Accuracy profile obtained in validation by applying weighted linear
r
since the bias did not exceed the values of 15% irrespective
to the concentration level.
3.3.5. Precision
The R.S.D. values presented in Table 1 were very low, the
relative standard deviation values for repeatability and inter-
mediate precision were between 0.4% and 1.6%, illustrating
the good precision of the proposed method. However, the
method sensitivity could still be improved since the R.S.D.
value for the LOQ is very low (1.5%).
3.3.6. Accuracy
The upper and lower -expectation tolerance limits ex-
pressed in ng ml−1 are presented in Table 1 as a function of
the introduced concentrations. As can be seen from the re-
sults, the proposed method was accurate, since the different
tolerance limits of the bias did not exceed the acceptance
limits (±15%) [27] for all the concentration levels tested in-
cluding the lowest one (0.3 ng ml−1).
3.3.7. Limit of quantiﬁcation and limit of detection
As the accuracy profile is comprised within the acceptance
limits, the LOQ was fixed to 0.3 ng ml−1, i.e. the smallest con-
centration level investigated. Indeed, precision and trueness
were demonstrated at this concentration level (Table 1). The
Legression (1/X2). OD has been estimated at 120 pg ml−1.
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3.4. Precolumn lifetime
In order to maintain an optimal lifetime of both precolumn
and analytical column, it is important to pre-centrifuge the
plasma samples, to add an organic modifier to the washing
liquid used for the fractionation step and to install a replace-
able in-line filter located between the sample injector and the
precolumn in order to protect the sieves and tubing from clog-
ging. These different recommendations have been taken into
account in the analytical protocol. Under the proposed ex-
perimental conditions, the precolumn was shown to be work
properly for over 1000 injections of 30l of plasma.
4. Conclusion
A new fully automated procedure was developed for
the LC–MS/MS determination of cyproterone acetate using
restricted-access material in a precolumn for sample process-
ing.
The developed method is selective towards endogenous
plasma components and the recovery of the analyte is close
to 100%. Its accuracy has been also assessed over a concen-
tration range from 0.3 ng ml−1 to 50 ng ml−1 when in our
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